Centre for Cardiovascular and Chronic Care, Faculty of Nursing, Midwifery & Health, University of Technology Sydney, Australia.
Heart Lung Circ. 2012 May;21(5):260-6. doi: 10.1016/j.hlc.2012.03.002. Epub 2012 Apr 13.
To assess the acute haemodynamic effects of nebulised frusemide in a stable advanced heart failure population.
In this randomised, double blind, placebo controlled trial, people with stable, advanced heart failure undergoing right heart catheterisation were randomised to receive either 40 mg (4 ml) of nebulised frusemide or 4 ml of normal saline. Following inhalation of the study medication, subjects' pulmonary pressures were recorded every 15 min for 1 h.
There were no significant changes in the weighted average time course data of the subjects (n=32) in either group over the study period, in particular no differences were observed in haemodynamic parameters between the two groups. Weighted average pulmonary capillary wedge pressure after 60 min in the frusemide group was 22.5 (SD 6.5) mmHg (n=14) compared to the placebo group's 24.0 (SD 7.3) mmHg (n=18), p=0.55. The frusemide group had a significantly greater change in the median volume of urine in the bladder over the study period (186 ml IQR 137.8-260.8) compared to the placebo group (76 ml IQR 39.0-148.0) p=0.02.
This study showed that nebulised frusemide had no significant clinical effect on the haemodynamic characteristics of the subjects.
评估雾化呋塞米在稳定的晚期心力衰竭人群中的急性血液动力学效应。
在这项随机、双盲、安慰剂对照试验中，正在接受右心导管检查的稳定、晚期心力衰竭患者被随机分配接受 40mg（4ml）雾化呋塞米或 4ml 生理盐水。吸入研究药物后，在 1 小时内每隔 15 分钟记录一次受试者的肺压。
在研究期间，两组受试者（n=32）的加权平均时间过程数据均无显著变化，两组之间的血液动力学参数也无差异。在呋塞米组 60 分钟时，肺动脉楔压的加权平均值为 22.5（SD 6.5）mmHg（n=14），而安慰剂组为 24.0（SD 7.3）mmHg（n=18），p=0.55。与安慰剂组（76ml IQR 39.0-148.0）相比，研究期间膀胱中尿液的中位数体积在呋塞米组中变化更大（186ml IQR 137.8-260.8），p=0.02。
本研究表明，雾化呋塞米对受试者的血液动力学特征没有显著的临床影响。
